Previous close | 13.80 |
Open | 13.80 |
Bid | 10.70 |
Ask | 14.50 |
Strike | 35.00 |
Expiry date | 2024-12-20 |
Day's range | 13.80 - 13.80 |
Contract range | N/A |
Volume | |
Open interest | N/A |
SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.